Pharma Foods International Co., Ltd.
Fiscal Year End Supplementary Materials for the Year Ended July 2026
For the fiscal year ended July 2026, the company implemented growth investments in the first half and shifted to profitability in the second half. Operating income increased 11.2% year-over-year, and net income attributable to owners of parent rose 439% year-over-year. Net sales decreased 3.1% year-over-year. Investments in a new factory and initiatives to strengthen the balance sheet alongside increased treasury stock progressed.
Key Figures
- Net Sales: 63,223 million yen (Year-over-Year -3.1%)
- Operating Income: 2,632 million yen (Year-over-Year +11.2%)
- Net Income Attributable to Owners of Parent: 1,988 million yen (Year-over-Year +439%)
AI要約
Overview of Performance
For the fiscal year ended July 2026, in line with the initial plan the company continued investments in the first half to drive growth and shifted to profit generation in the second half. Revenue improvement was strengthened in the fourth quarter, resulting in operating income increasing 11.2% year-over-year and net income improving significantly by 439% year-over-year. Net sales decreased 3.1% year-over-year, while segment-level investments and optimization progressed in both BtoC and BtoB. Growth investments related to the new factory construction and improvements in financial soundness are underway.
Impact on Shareholders and Financial Stability
Tangible fixed assets increased due to fixed asset additions and the new factory investment. Current assets slightly declined, but the year-end equity ratio improved to 37.5%. Through increased retained earnings and an improved equity ratio, funding for growth investments has been secured. Cash and cash equivalents remained stable at the fiscal year-end.
Pharma Foods International Co., Ltd.
Company overview · Stock price · Financial data · All IR
